ClinicalTrials.gg
CompletedNCT02034565Updated Aug 22, 2016Results posted

Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects

A Phase 1 interventional study of Apixaban in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-22.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to assess the oral bioavailability of Apixaban solution formulation (Treatment B, 10 mg as 25 mL x 0.4 mg/mL) relative to Apixaban tablets (Treatment A, 10 mg as 2 x 5 mg tablets) in healthy subjects.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects as determined by no deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness or relevant trauma (e.g., history of chronic hypertension, bacterial endocarditis, hemorrhagic stroke, motor vehicle accident resulting in significant head trauma or internal injuries)
  • History or evidence of abnormal bleeding or coagulation disorder (e.g., easy bruising or gingival bleeding, prolonged bleeding after dental extraction, postpartum, or after trauma, wounds or surgery)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Treatment A: Apixaban tablet

    Apixaban Film coated Tablet Single dose 10 mg orally

    Drug: Apixaban

  • Experimental
    Treatment B: Apixaban oral solution

    Apixaban Solution Single dose 10 mg orally

    Drug: Apixaban

Interventions

06

What researchers measure

Primary outcomes

  1. Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban

    Serial blood samples for pharmacokinetic analysis were collected at selected times up to 72 hours after each dose. Maximum observed plasma concentration (Cmax) is measured in nanograms per milliliter (ng/mL)

    Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose per intervention

  2. Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinite Time AUC(INF) of Apixaban

    Serial blood samples for pharmacokinetic analysis were collected at selected times up to 72 hours after each dose. AUC(INF) is measured in nanogram hours per milliliter (ng\*h/mL)

    Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose per intervention

  3. Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban

    Serial blood samples for pharmacokinetic analysis were collected at selected times up to 72 hours after each dose. AUC(0-T) is measured in nanogram hours per milliliter (ng\*h/mL)

    Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose per intervention

Secondary outcomes

  1. Number of Participants With Serious Adverse Events (SAEs), Treatment-Related Adverse Events (AEs), Deaths or Discontinuation of Study Drug Due to AEs

    AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v13).

    Time frame: Day 1 to 30 days after last dose of study drug

  2. Number of Participants With Marked Laboratory Abnormalities

    Clinical laboratory tests were performed pre-study and at selected times throughout the study. Marked laboratory abnormalities were defined as laboratory assessments meeting the following investigator-specified criteria: Leukocytes \< 0.9\* lower limits of normal (LLN), absolute neutrophils + bands \<= 1.500 10\*3 cells/microliter, white blood cells (WBC) urine value \>= 2+. These laboratory abnormalities were not considered clinically significant and therefore not adverse events.

    Time frame: Pre-study screen (Day -1) to Day 8 or day of study discharge

07

Results

Posted Aug 22, 2016

Participant flow

Participant flow — Overall Study
MilestoneTreatment A, Then Treatment BTreatment B, Then Treatment A
Started77
Completed67
Not completed10
Withdrew: Adverse event10

Outcome measures

PrimaryAdjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban

Serial blood samples for pharmacokinetic analysis were collected at selected times up to 72 hours after each dose. Maximum observed plasma concentration (Cmax) is measured in nanograms per milliliter (ng/mL)

Time frame:
Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose per intervention
Reported as:
Geometric mean · ng/mL
Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban
ng/mLTreatment A: Apixaban TabletTreatment B: Apixaban Oral Solution
Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban293.994 (245.998 to 351.354)287.164 (242.331 to 340.291)
Statistical analysis
  • Treatment A: Apixaban Tablet vs Treatment B: Apixaban Oral Solution · Ratio of adjusted geometric means: 0.977 · 90% CI 0.756 to 1.261
PrimaryAdjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinite Time AUC(INF) of Apixaban

Serial blood samples for pharmacokinetic analysis were collected at selected times up to 72 hours after each dose. AUC(INF) is measured in nanogram hours per milliliter (ng\*h/mL)

Time frame:
Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose per intervention
Reported as:
Geometric mean · ng*h/mL
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinite Time AUC(INF) of Apixaban
ng*h/mLTreatment A: Apixaban TabletTreatment B: Apixaban Oral Solution
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinite Time AUC(INF) of Apixaban2712.477 (2414.339 to 3047.432)2848.968 (2557.946 to 3173.101)
Statistical analysis
  • Treatment A: Apixaban Tablet vs Treatment B: Apixaban Oral Solution · Ratio of adjusted geometric means: 1.050 · 90% CI 0.938 to 1.176
PrimaryAdjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban

Serial blood samples for pharmacokinetic analysis were collected at selected times up to 72 hours after each dose. AUC(0-T) is measured in nanogram hours per milliliter (ng\*h/mL)

Time frame:
Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose per intervention
Reported as:
Geometric mean · ng*h/mL
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban
ng*h/mLTreatment A: Apixaban TabletTreatment B: Apixaban Oral Solution
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban2668.310 (2372.198 to 3001.385)2784.366 (2497.506 to 3104.175)
Statistical analysis
  • Treatment A: Apixaban Tablet vs Treatment B: Apixaban Oral Solution · Ratio of adjusted geometric means: 1.043 · 90% CI 0.933 to 1.167
SecondaryNumber of Participants With Serious Adverse Events (SAEs), Treatment-Related Adverse Events (AEs), Deaths or Discontinuation of Study Drug Due to AEs

AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v13).

Time frame:
Day 1 to 30 days after last dose of study drug
Reported as:
Number · participants
Number of Participants With Serious Adverse Events (SAEs), Treatment-Related Adverse Events (AEs), Deaths or Discontinuation of Study Drug Due to AEs
participantsArm A: Apixaban TabletArm B: Apixaban Oral Solution
SAE00
Treatment-Related AE01
Deaths00
Treatment-Related Deaths00
Discontinuation of Study Drug Due to AEs10
SecondaryNumber of Participants With Marked Laboratory Abnormalities

Clinical laboratory tests were performed pre-study and at selected times throughout the study. Marked laboratory abnormalities were defined as laboratory assessments meeting the following investigator-specified criteria: Leukocytes \< 0.9\* lower limits of normal (LLN), absolute neutrophils + bands \<= 1.500 10\*3 cells/microliter, white blood cells (WBC) urine value \>= 2+. These laboratory abnormalities were not considered clinically significant and therefore not adverse events.

Time frame:
Pre-study screen (Day -1) to Day 8 or day of study discharge
Reported as:
Number · participants
Number of Participants With Marked Laboratory Abnormalities
participantsArm A: Apixaban TabletArm B: Apixaban Oral Solution
Leukocytes, Low11
Absolute Neutrophils + Bands, Low11
WBC, Urine, High01

Adverse events

Collected over From first dose to last dose plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Apixaban Tablet—0/14 (0%)4/14 (28.6%)
Arm B: Apixaban Oral Solution—0/13 (0%)2/13 (15.4%)
Most frequent other events
Most frequent other events
EventArm A: Apixaban TabletArm B: Apixaban Oral Solution
HeadacheNervous system disorders2/141/13
Throat irritationRespiratory, thoracic and mediastinal disorders0/141/13
ConstipationGastrointestinal disorders1/140/13
ToothacheGastrointestinal disorders1/140/13
Vessel puncture site haematomaGeneral disorders1/140/13
FatigueGeneral disorders1/140/13
DyspepsiaGastrointestinal disorders1/140/13
EructationGastrointestinal disorders1/140/13

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)All Treatment Groups
Mean36 (28 to 44)
Sex: Female, Male
Sex: Female, Male(Participants)All Treatment Groups
Female2
Male12
08

Study locations

1 site
  • Mds Pharma Services
    Neptune, New Jersey 07753, United States
09

References and documents

Publications

  • Song Y, Wang X, Perlstein I, Wang J, Badawy S, Frost C, LaCreta F. Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects. Clin Ther. 2015 Aug;37(8):1703-12. doi: 10.1016/j.clinthera.2015.05.497. Epub 2015 Jul 15. PubMed 26188837 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 6 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2014
First posted
Jan 13, 2014
Start
Feb 2010
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Aug 22, 2016
Last update
Aug 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02034565
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jan 13, 2014
Start date
Feb 2010
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Aug 22, 2016
Last update
Aug 22, 2016

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion